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Introduction
Multiple endocrine neoplasia type 2 (MEN-2) is a rare auto-
somal dominant disorder, which is estimated 2.5 per 100,000
in the general population1). Among the MEN 2 group, MEN-
2B syndrome is not only the least common but also the most
aggressive form of MEN-2. It is charaterized by tumors of
endocrine glands, consisting of medullary thyroid carcinoma
(MTC), pheochromocytoma, and mucosal neuromas of the
tongue, lips and other sites, which is disorganized growth of
peripheral nerve axons, and marfanoid habitus. The main
cause of death in patients with MEN 2B is known as MTC.
MEN 2B has high penetrance of MTC, early disease onset in
the first year of life, higher morbidity and mortality rates com-
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pared with other MEN 2 group. These facts explain the
reason why early diagnosis of this syndrome is critical2, 3).
A genetic predisposition to MEN-2 is caused by germ line-
activating mutations of the RET proto-oncogene. The ability
of molecular analysis of the RET proto-oncogene in recent
decades made the earlier diagnosis of MEN 2B possible and
the better prognosis of this syndrome4). We encountered two
cases of MEN-2B with prophylactic thyroidectomy by early
diagnosis of RET proto-oncogene, and report the cases with
review of literature.
Case Report
1. Patient 1
A 13-month-old boy visited Severance Children’s Hospital
to perform further evaluation and adequate management for
MEN 2B. His mother took total thyroidectomy 5 years ago
and lately, modified neck node dissection 2 weeks ago due to
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thyroid carcinoma (MTC), pheochromocytoma and mucosal neuromas of the tongue, lips and other sites.
Especially, MTC is the main cause of death in patients who have not received early prophylactic treatment, and
MTC in MEN 2B represents more aggressive progress than that of MEN 2A. We encountered two cases of multiple
endocrine neoplasia type 2B. One was a 13 month old boy who had familial history of MEN 2B without any
symptoms, and the other was a 6-year old boy who manifested multiple mucosal neuromas of the tongue which
had been aggravated in four months. Their genetic analysis revealed a point mutation 918th cordon in the RET
proto-oncogene. Both of them underwent an operation for prophylactic total thyroidectomy and the 6 year old
boy’s specimen turned out to be thyroid medullary carcinoma. We encountered two cases of MEN 2B with
prophylactic thyroidectomy by early diagnosis of RET proto-oncogene, and report the cases with review of
literature. (J Korean Soc Pediatr Endocrinol 2010;15:138-144)
Multiple endocrine neoplasia type 2b; Proto-oncogene proteins c-ret
대한소아내분비학회지 :제 15 권 제2호 2010 ■증 례■
Two Cases of Multiple Endocrine Neoplasia Type 2B, Early Diagnosis by Genetic Analysis and Prophylactic Total Thyroidectomy 139
recurred MTC. We found out that he had thick lumpy lips
(Fig. 1) and bilateral small protruding mass (Fig. 2) inside his
mouth which suggested mucosal neuromas on his physical
examination. He lacked a marfanoid face, although his mo-
ther had this appearance.
Blood test includes the complete blood count (CBC),
electrolytes, liver enzyme, calcium and phosphate were
checked, and thyroid function test; triiodothyronine (T3), free
thyroxine (T4), thyroid stimulating hormone (TSH) were
149.36 ng/dL, 1.28 ng/dL, 1.45 μIU/mL, respectively (Table
1A). We took calcitonin stimulation test for detection of pri-
mary secretory product of malignant C-cells of MTC, which is
the marker of medullary thyroid carcinoma in case of MTC.
His calcitonin level was elevated to 153.87 pg/mL, while nor-
mal range is 0 to 10 pg/mL. Basal calcitonin level, 5 minutes
and 10 minutes after calcium infusion (2 mg/kg) calcitonin
level were 84.10l g/mL, 76.44 pg/mL and 55.65 pg/mL res-
pectively (Table 2).
There was no evidence of the other thyroid and parathy-
roid abnormalities except several hypoechoic nodules sugge-
sting colloid cyst in thyroid gland on the thyroid scan.
Plasma epinephrine and norepinephrine were checked,
the former was 0.036 ng/mL (normal range: 0.0 to 0.3 mg/
mL), the latter was 0.199 ng/mL (normal range: 0.0 to 0.8 ng/
Table 1. The patients' endocrinologic laboratory results
Patient 1 Initial
2 days after
operation
15 months after
operation
2 years after
operation
4 years after
operation
Calcium (mg/dL)
Phosphate (mg/dL)
PTH (pg/mL, 10 - 57)
T3 (ng/dL, 80 - 200)
fT4 (ng/dL, 0.7 - 1.9)
TSH (μIU/mL, 0.3 - 4.0)
Calcitonin (pg/mL, 0 - 10)
10.7
5.5
9.12
149.4
1.28
1.45
153.9
8.7
4.43
6.8
2.28
152.2
1.48
3.97
9.5
6.3
161.7
1.80
1.48
9.2
5.3
147.5
1.21
7.95
9.2
5.5
10.0
140.4
1.48
0.73
4.10
Patient 2 Initial
2 days after
operation
6 months after
operation
1 year after
operation
2 years after
operation
Calcium (mg/dL)
Ionized calcium (mg/dL)
Phosphate (mg/dL)
PTH (pg/mL, 10 - 57)
T3 (ng/dL, 80 - 200)
fT4 (ng/dL, 0.7 - 1.9)
TSH (μIU/mL, 0.3 - 4.0)
Calcitonin (pg/mL, 0 - 10)
9.6
4.6
121.9
1.27
4.14
288.7
6.8
7.2
1.61
64.3
1.04
5.61
19.2
8.8
5.1
5.94
154.2
1.83
0.75
1.50
9.6
5.7
2.25
161.7
1.81
3.52
8.7
5.4
7.19
156.2
1.79
2.93
8.60
Abbreviations: PTH, parathyroid hormone; T3, triiodothyronine; fT4, free thyroxine; TSH, thyroid stimulating hormone
Fig. 1. Patient 1; thick bumpy lip.
Fig. 2. Patient 1; small, soft, protruding mass inside on his lip,
which suggests mucosal neuroma.
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mL). Urine epinephrine (normal range: 0 to 20 μg/day) and
norepinephrine (normal range: 15.0 to 80.0 μg/day) were 1.0
μg/day and 1.5 μg/day. Urine metanephrine (normal range:
0.0 to 1.3 mg/day) and vanillylmandelic acid (normal range:
0.0 to 8.0 mg/day) were 0.084 mg/day and 0.14 mg/day, res-
pectively. These suggest that there is no pheochromocytoma.
The boy and his mother took RET proto-oncogene muta-
tion analysis and it showed a missense mutation at 918th
codon in exon 16, which confirmed MEN 2B.
According to the principle for the highest risk of MEN 2B5),
he had prophylactic total thyroidectomy with cervical lymph
node dissection on the 8th day of admission. Pathology con-
firmed that his thyroid gland was normal and there was no C-
cell hyperplasia which is usually seen in cases of MEN 2B.
Even though he preserved parathyroid gland, his blood
test showed calcium level as 8.7 mg/dL after surgery, while
normal range is 8.8 to 10.8 mg/dL. He was treated with oral
calcium (elemental calcium 520 mg/day) and Vitamin D (0.5
g/day). Levothyroxine 0.05 mg/day was administrated due to
the possibility of hypothyroidism. He was discharged without
any post-operative complications and has visited to the
outpatient clinic regularly until these days.
2. Patient 2
A boy, 6 and 1/2 years old, visited Severance Children’s
Hospital with his small nodular lesion on tongue tip (Fig. 3)
which became larger than it had been 4 months ago. He had
mild bumpy lips (Fig. 4), and his eyelid seemed to be slightly
chucky. On these accounts, we were doubting of MEN 2B
because of his morphology, which seemed to be marfanoid
feature. At first, he took thyroid sonogram, and hypoechoic
nodules were found (Fig. 5). The observation indicated a sus-
picion of malignancy.
After 1 week later, he was hospitalized for diagnosis. The
results of his blood sample including CBC, electrolytes and
other serum material analysis were within normal range. Cal-
cium and phosphorus were 9.6 mg/dL and 4.4 mg/dL, respec-
tively (Table 1B). His basal calcitonin level was 241.40 pg/
mL, stimulated calcitonin by pentagastrin were 227.60 pg/mL
at 5 minutes after and 309.94 pg/mL at 15 minutes after, these
Fig. 4. Patient 2; bumpy lips.
Fig 5. Patient 2’s thyroid sonogram; multiple small colloid cyst
(indicated by the white arrowheads on both sides) and well-
defined heterogeneous echogenic mass with small cystic
changes (outlined by the white dots), suspicious malignancy.
Fig. 3. Patient 2; small, well defined nodular lesion on his tongue
tip, after mucosal biopsy.
Table 2. The results of serum calcitonin level after cal-
cium infusion (patient 1) and pentagastrin infusion (patient
2)
0 min 5 min 10 min
Patient 1: calcitonin (pg/mL, 0 - 10)
Patient 2: calcitonin (pg/mL, 0 - 10)
84.10
240.40
76.44
227.60
55.65
309.94
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basal and stimulated calcitonin levels were suggesting a
possibility of MEN 2B (Table 2).
He underwent tongue biopsy, the sample from the biopsy
of tongue tip was sent for pathologic diagnosis. In the final
pathologic report, there was an irregular proliferation of ner-
ve fibers, neuroma, increasing the possibility of MEN 2B (Fig.
6). Also he was examined by an ophthalmologist. There was
no abnormal finding such as conjunctival neuroma.
As the tool of diagnosis for pheochromocytoma, the results
from abdominal computed tomogram (CT) were normal ex-
cept mild intrahepatic ductal dilatation.
Taken together, the factors from laboratory test and radio-
logic test indicated a possibility of MEN 2B. His blood sample
was taken for genetic analysis, specifically RET proto-onco-
gene. His genetic analysis revealed missense mutation at 918th
codon in the RET proto-oncogene, which confirmed him
MEN 2B.
As mentioned earlier, MEN 2B is autosomal dominant inhe-
ritance, we proposed to take familial genetic analysis. The re-
sults from his mother and elder brother were negative, and
his father refused to take this study although he did not
showed any feature of MEN 2B.
He underwent a successful operation for prophylactic total
thyroidectomy with modified neck node dissection and his
specimen turned out to be thyroid medullary carcinoma (Fig.
7). He was administrated with elementary calcium (2.2 g/
day), vitamin D (0.5 g/day), levothyroxine (0.1 mg/day) after
surgery for treatment of hypothyroidism and hypoparathy-
roidism despite of preserved parathyroid glands. For last two
years, he regularly has come for follow- up visits in outpatient
clinic without any recurrence.
Fig 7. Patient 2; pathologic finding of thyroid. Tumor nests composed of regulary sized round cells with
abundant granular cytoplasm (outlined by the black dots), which is a finding of medullary carcinoma.
Hematoxylin and eosin were used for left slide, and immunocheminal stain with carcinoembryogenic antigen
(CEA) was used for right slide. The original magnification of the both was × 200.
Fig. 6. Patient 2; pathologic finding of tongue biopsy. Irregular proliferation of nerve fibers (outlined by the
black arrowheads), possibly neuromas. Hematoxylin and eosin were used; the original magnification of the left
slide was × 40, that of the right side was × 200.
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Discussion
MTC is a rare type of thyroid tumor, and it is reported in al-
most every case associated with MEN 2B6). The most common
clinical presentation of MTC is thyroid nodule, either single or
multinodular, and the prevelance varies from 5 to 10% among
thyroid cancer and 0.4 to 1.4% among thyroid nodules7, 8).
Only advanced metastatic MTC can present the clinical feature
of diarrhea or flushing9). In the past, the diagnosis of MTC
was not set until the disease had clinical evidence. Inevitably,
it is the reason why MTC was found at either an advanced or
incurable stage10).
It is well known that MTC can be cured when only the
lesion is intrathyroid or few lymph node metastasis11). MTC in
MEN 2B is showing extremely aggressive characteristics
because it spreads early on and it is not only chemoresistant
but also radioresistant. Therefore, it emphasizes the signifi-
cance of the early diagnosis. Among the several attempts to
distinguish the presence of MTC, calcitonin, mainly secreted
from parafollicular C cell, is important as an excellent tumor
marker because of its increased production by the presence
of malignant transformed C cells12). When a basal calcitonin
level is elevated above 30 pg/mL, 37.1% of the patients found
MTC or nodal metastasis13). Even with normal basal calcitonin
levels, the stimulated calcitonin level may allow the detection
of MTC at early stage. Over 92% of previous cases showing
pathologic peak calcitonin level stimulated by the use of sec-
retagogues (pentagastin or calcium), which is considered nor-
mal in case of less than 10 pg/mL14, 15), revealed that MTC was
present. Unfortunately, the role of basal and stimulated calci-
tonin levels is limited because the diagnosis is usually made
after the marked development of their disease. Moreover, in
20% of patients, who are already documented MTC of C-cell
hyperplasia in histologic examinations, their pentagastrin-sti-
mulated calcitonin levels are within normal range16). In a
word, truly prophylactic thyroidectomy based upon basal and
stimulated calcitonin level is impossible. Despite of the
suspected MEN 2B, that is the reason why we could not
undergo thyroidectomy, only depending on the evidence of
the patients’ pathologic calcitonin levels.
The RET, rearranged during transfection, is a proto-onco-
gene. Recent advances in molecular biology are allowing us
to understand the mechanism of carcinogenesis and genetic
alternation associated MTC. In 1993, germ line mutations in
the RET proto-oncogene, located at 10q11.2, were identified
in patients with MEN 2 group, which include MEN 2A, MEN
2B and Familial MTC17). A single activating mutation of one
allele is enough to process neoplastic transformation, and its
mutations are noted in over 95% of MEN 2 index cases18).
When this genetic test reports a higher rate of true positive
and lower rate of false negative than the calcitonin test, it
achieves early diagnosis of MEN 2 syndrome hopefully before
the neoplastic changes would begin in the thyroid10).
Interestingly, genetic analysis provides the correlations of
genetype and phenotype, and it can be a clue which deter-
mines the optimal timing of prophylactic thyroidectomy19).
Kloos et al.5) separated patient risk group level A, B, C and D,
according to the risk for MTC development and growth. The
highest risk, level D, involves mutated codon 918 and 883,
thus the patients in level D are recommended for undergoing
thyroidectomy within the first months of life. The investiga-
tors emphasize that microscopic MTC is not unusual in pa-
tients with these cordons, and even metastasis during the first
year of life is noted. The patients visited Severance Children’s
Hospital have been managed according to the paradigm of
level D.
The optimal treatment goal is to prevent hereditary MTC by
performing early thyroidectomy before malignant transforma-
tion takes place. Thyroidectomy on the basis of positive
genetic analysis and before the development of MTC is truly
prophylactic, while thyriodectomy after the development of
MTC is only therapeutic. The timing of prophylactic thyroi-
dectomy determines the prognosis of patients with MEN 2B,
which emphasize the importance of early detection and im-
mediate treatments20). Recently, less than 5% of mortality rate
was reported with early prophylactic thyroidectomy, com-
pared with 15% to 20% of rate in the past.
Postoperatively, regular follow-up is the key for early
detection of recurrence. On each visit for follow-up, calciton-
in levels should be examined. Because calcitonin is an excel-
lent tumor marker, after surgery elevated calcitonin level is
the solid indicator of persistent or recurrent disease18, 21). We
also have examined the patients’ calcitonin levels to check the
MTC recurrence. For successful prophylactic thyroidectomy,
screening for pheochromocyroma must be done annually
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from age of eight in cases of ATA-C and ATA-D5). Also, repla-
cement therapy for the hypoparathyroidism and secondary
hypocalcemia may be required. Our Patients have been treat-
ed on levothyroxine, elementary calcium and Vitamin D, in
accordance with their laboratory results.
In Korea, there are not many case reports about MEN
groups; furthermore, the majority of them are subjected to
MEN 2A and familial medaullary thyroid carcinoma (FMTC).
Due to its rarity, there are just six clinical cases for MEN 2B
until present date22-27). Within these cases, two are tested by
genetic analysis, their genetic findings showed 918 codon’s
mutation25, 27). Only one patient, mentioned in this report as
Patient 1, was pediatric and he was the sole person who
treated by prophylactic thyroidectomy27).
According to our experience, findings such as either neu-
roma or familial genetic study strongly indicate the presence
of MEN 2B, and it can be early diagnosed through genetic
analysis. In past two cases, successfully diagnosing MEN 2B
based on genetic analysis before clinical symptoms appear on
the outside followed by truly prophylactic thyroidectomy is a
key strength of our case report. The much better prognoses
are anticipated in patient with MEN 2B when treated in a
timely manner.
한 글 요 약
를 이용한RET proto-oncogene
다발성 내분비 종양제 형의 조기진단으로2B
예방적 갑상선 절제술을 시행한 례2
연세대학교 의과대학 소아과학교실
이화영 권아름 채현욱 김호성 김덕희ㆍ ㆍ ㆍ ㆍ
다발성내분비종양제 형은갑상선수질암 크롬친화성2 ,
종양 다발성장기에나타나는신경종을포함하는내분비종,
양으로 이중갑상선수질암은다발성내분비종양제 형을, 2
가진환자에서 주요 사망 원인으로알려져있다 최근 분자.
생물학의발전으로 을이용하여무증상RET proto-oncogene
의 환자들에서도 다발성 내분비 종양의 조기진단이 가능하
게되었으며 이로인해예방적인갑상선절제술이가능하게,
되었다 저자들은 검사를 통해 다발성. RET proto-oncogene
내분비종양제 형을진단받고예방적갑상선절제술을시2
행한 예를경험하였기에문헌고찰과함께보고하는바이다2 .
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